Litigation Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)
| Docket | ⤷ Subscribe | Date Filed | 2017-06-19 |
| Court | District Court, D. Delaware | Date Terminated | 2020-04-20 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Parties | BELCHER PHARMACEUTICALS, LLC | ||
| Patents | 9,283,197 | ||
| Attorneys | J. Clayton Athey | ||
| Firms | Dorsey & Whitney (Delaware) LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Belcher Pharmaceuticals, LLC v. Hospira, Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Subscribe .
Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-12-13 | 118 | Notice of Service | 's Invalidity Contentions Regarding U.S. Patent No. 9,283,197 filed by Hospira, Inc..(Haney, Megan) (Entered…2017 20 April 2020 1:17-cv-00775 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-03-31 | 244 | Opinion | bioequivalent product infringes U.S. Patent No. 9,283,197 (“the ’197 Patent”) under the doctrine of equivalents…that it does not infringe the ’197 Patent and, further, that the Patent is invalid and/or unenforceable… infringe the ’197 Patent under the doctrine of equivalents, (2) the ’197 Patent is invalid as obvious…D.I. 201 at ¶¶ 3-5) II. Patent-in-Suit 8. The ’197 Patent, entitled “More Potent and …a named inventor on more than 39 U.S. patents, including patents related to drug development, formulation | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
